Cost-effectiveness analysis of Sacituzumab Tirumotecan as second-line therapy for EGFR-TKI-resistant, EGFR-Mutated advanced NSCLC in China.

Authors

Jing He, Jialin Yu, Ruixuan Liu, Qing Yang

Published in

Expert review of pharmacoeconomics & outcomes research. Jun 21, 2026. Epub Jun 21, 2026.

Abstract

This study estimated the cost-effectiveness of sacituzumab tirumotecan (Sac-TMT) versus pemetrexed-platinum chemotherapy as second-line therapy for advanced EGFR-mutated non-small cell lung cancer (NSCLC) in China.
A partitioned survival model based on the OptiTROP-Lung04 trial was developed from the Chinese healthcare perspective. The incremental cost-effectiveness ratio (ICER) was compared with a willingness-to-pay (WTP) threshold of $26,889.37/QALY. One-way, two-way, and probabilistic sensitivity analyses, together with scenario analyses, tested the robustness of the findings.
The base-case analysis results showed that over 10 years, Sac-TMT gained 0.86 additional QALYs at an incremental cost of $64,255.79, yielding an ICER of $75,704.42/QALY, exceeding the WTP threshold. Key drivers were patient body weight, the per-unit cost of Sac-TMT (180 mg), and the health utility value for the progressive disease state. The probability of Sac-TMT being cost-effective at the WTP threshold of $26,889.37/QALY was 0%. Patient assistance program reduced the ICER to $46,354.36/QALY. A price reduction exceeding 73.81% would bring the ICER below the WTP threshold.
At current prices, Sac-TMT is not cost-effective as second-line therapy for advanced EGFR-mutated NSCLC in China.

PMID:
42324853
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.